The company has demonstrably improved the course of an innovative treatment for ATTR-CM, leveraging the compound. Preliminary patient information indicates promising benefits for those diagnosed from the severe illness. https://biotech029937.blogerus.com/64156614/bridgebio-advances-attr-cm-treatment-through-the-drug